Drugs / GEDIVUMAB
GEDIVUMAB
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02284607 | Nov 2014 → Mar 2015 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01877785 | Jul → Nov 2013 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT02623322 | Oct 2016 → Nov 2017 | influenza | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02293863 | Jan 2015 → May 2017 | influenza | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT01980966 | Nov 2013 → Jun 2014 | — | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEDIVUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298040 ↗ |
| Known as | MHAA4549A | “MHAA4549A, a human monoclonal antibody targeting the hemagglutinin stalk region of influenza A virus (IAV), is being developed as a therapeutic for patients hospitalized with...” PMID 28807912 ↗ Oct 2017 |
| Known as | RG7745 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298040 ↗ |
| Known as | RO6876802 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298040 ↗ |
| Modality | Monoclonal antibody | “MHAA4549A is a human monoclonal immunoglobulin (Ig) G1 antibody” PMID 27381392 ↗ Aug 2016 |
| Route | Intravenous | “single intravenous dose of 1.5, 5, 15, or 45 mg/kg MHAA4549A” PMID 27381392 ↗ Aug 2016 |